Lupin Limited — Updates, 14-05-2025: Press Release

Lupin has announced a board meeting on the financial results for the quarter and half-year. The company posted 12.9% sales growth to INR 22,192 Cr in FY2025, led by strong performance in North America (15.9%) and India (13.8%). EBITDA jumped 39.4% with margins reaching 24.7%, while PAT soared 70.8% to INR 3,306 Cr. Net debt turned negative at INR -310 Cr, signaling a robust balance sheet. Lupin secured 7 US FDA ANDA approvals, launched 2 products, and holds 138 generics in the US, remaining the 3rd largest player. R&D spend stayed high at 8% of sales.